Sirtex, a leading developer and manufacturer of targeted, innovative liver cancer therapies, today announced the results of a Phase I study evaluating the safety and efficacy of concurrent treatment using capecitabine in combination with Selective Internal Radiation Therapy (SIRT), also known as radioembolization, using SIR-Spheres® microspheres to treat liver tumors. The data were released at the 2011 Annual Meeting of the American Society of Clinical Oncology by lead investigator Steven J. Cohen, M.D., Chief of Gastrointestinal Medical Oncology at Fox Chase Cancer Center and Associate Medical Director for Fox Chase Cancer Center Partners.
